Telehealth Treatment for Alcohol Use Disorder
Launched by RIA HEALTH · Feb 17, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help people with alcohol use disorder, a condition where individuals struggle to control their drinking. Participants will be randomly placed into two groups: one group will use the Ria Treatment Platform, which is an online program that offers medical help, medications, coaching sessions, educational videos, and a special breathalyzer to monitor their alcohol levels. The other group will be on a waitlist and will not receive immediate treatment. The trial will last for three months, during which researchers will track how much alcohol participants consume and any related issues they might face.
To be eligible for this trial, participants must have alcohol use disorder, but they need to be able to understand and agree to take part in the study. Everyone involved, regardless of age or gender, will be closely monitored and supported throughout the program. This trial aims to find out if this telehealth approach can effectively help people reduce their drinking and improve their overall well-being.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • alcohol use disorder
- Exclusion Criteria:
- • inability to provide informed consent
About Ria Health
Ria Health is a leading innovator in digital health solutions focused on addressing alcohol use disorder. By combining evidence-based clinical practices with advanced technology, Ria Health offers personalized treatment programs that empower individuals to manage their alcohol consumption effectively. Through a blend of telehealth services, mobile app support, and continuous monitoring, Ria Health aims to improve patient outcomes and enhance the overall experience of recovery. Committed to advancing research in the field, Ria Health actively sponsors clinical trials to evaluate the efficacy of its programs, contributing valuable insights to the landscape of addiction treatment.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stanford, California, United States
Patients applied
Trial Officials
John Mendelson, MD
Principal Investigator
Ria Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials